|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.14 - 4.37|
|52 Week Range||1.08 - 5.71|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
On a per-share basis, the Needham, Massachusetts-based company said it had a loss of 61 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
The Boston firm unveils positive results from its Phase 3 study of duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent. Verastem said its drug, duvelisib, reduced the risk of disease progression or death in patients by 48 percent when compared with the current standard of care, Novartis's Arzerra. The oral drug was tested in 319 patients suffering from chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who did not respond to initial treatment or whose cancer had relapsed.
The 2017 American Society of Clinical Oncology annual meeting is taking place in Chicago from last Friday through Tuesday. There have already been several companies that have updated shareholders with ...
The Needham, Massachusetts-based company said it had a loss of 35 cents per share. Losses, adjusted for stock option expense, came to 32 cents per share. The results surpassed Wall Street expectations. ...
Verastem Inc (NASDAQ: VSTM ) is a biopharmaceutical company that focuses on discovering and developing therapies for the treatment of patients with cancer. Verastem acquired a license agreement from Infinity ...